Long-term outcome after pulmonary retransplantation

Martin Strueber, MD,^a Stefan Fischer, MD, MSc,^a Jens Gottlieb, MD,^b Andre R. Simon, MD,^a Heidi Goerler, MD,^a Bernhard Gohrbandt, MD,^a Tobias Welte, MD,^b and Axel Haverich, MD^a

Earn CME credits at
<http://cme>.

See related editorial on page 226.

Objective: Bronchiolitis obliterans syndrome has become the most limiting factor for long-term outcome after lung transplantation. Redo lung transplantation was performed for end-stage bronchiolitis obliterans syndrome. Long-term outcome was compared with that after primary lung transplantation as well as with other indications for retransplantation.

Methods: Of 614 lung transplantation procedures performed at our institution, 54 (8.5%) were redo transplants. These were stratified into different groups according to the indication for redo transplantation, including chronic graft failure/bronchiolitis obliterans syndrome, acute graft failure, and posttransplantation airway complications. Long-term survival was compared with that of the primary lung transplantation cohort, thereby respecting the need for pretransplant mechanical ventilatory support in a subanalysis. In addition, recurrence of bronchiolitis obliterans syndrome after redo lung transplantation was compared with the occurrence of bronchiolitis obliterans after primary transplantation.

Results: A 1-year survival of 50% was achieved after redo lung transplantation for acute graft failure and airway complications as well as after primary lung transplantation in patients with pretransplant ventilatory support. Retransplantation for bronchiolitis obliterans syndrome revealed superior 1- (78%) and 5-year (62%) survivals, which were not different from those of first-time lung transplant recipients. In addition, we found a similar incidence of bronchiolitis syndrome after retransplantation for BOS compared with its occurrence after primary lung transplantation.

Conclusion: Redo lung transplantation for end-stage bronchiolitis obliterans syndrome leads to acceptable long-term outcome in selected patients. Future analyses of redo lung transplantation data should generally stratify bronchiolitis obliterans syndrome from other indications with higher mortality.

From the Hannover Thoracic Transplant Program, Division of Thoracic- and Cardiovascular Surgery^a and Department of Respiratory Medicine,^b Hannover Medical School, Hannover, Germany.

Received for publication Sept 20, 2005; revisions received Dec 18, 2005; accepted for publication Dec 22, 2005.

Address for reprints: Martin Strüber, MD, Director, Hannover Thoracic Transplant Program, Division of Thoracic and Cardiovascular Surgery, Hannover Medical School, Carl Neuberg Str1, 30625 Hannover, Germany (E-mail: strueber@thg.mh-hannover.de).

J Thorac Cardiovasc Surg 2006;132:407-12
0022-5223/\$32.00

Copyright © 2006 by The American Association for Thoracic Surgery

doi:10.1016/j.jtcvs.2005.12.059

Lung transplantation (LTx) has become an established therapeutic modality for a variety of end-stage pulmonary diseases. However, since most technical obstacles during transplantation and common complications in the early phase after transplantation have been properly addressed, the remaining major challenge is the prevention and treatment of bronchiolitis obliterans syndrome (BOS). In the literature the overall incidence of BOS within the first 5 years after primary LTx is approximately 50%.¹ In addition, data suggest a lower chance for 10-year survival after LTx in patients with BOS. Currently, BOS is the cause of

Abbreviations and Acronyms

BOS = bronchiolitis obliterans syndrome

LTx = lung transplantation

re-LTx = pulmonary retransplantation

death in 17% of patients after LTx.² This is, beside infection, the second leading cause of death and the number is growing with the increasing number of LTx procedures worldwide. BOS is a multifactorial disease and, apparently, the prevention of BOS by any single means is impossible.³ Although promising approaches to the prevention of BOS have been reported,⁴ strategies that have used new immunosuppressants have not provided satisfactory results.

Various treatment protocols for BOS were also suggested.⁵ However, the delay of further deterioration of lung function in BOS patients was called successful and many studies did not address the possible role of acute rejection or infection episodes after LTx in the context of BOS development.^{6,7} Therefore, some improvements seen in the course of BOS may be due to successful treatment of acute rejection or infection.

End-stage BOS eventually leads to lung failure. Therefore, it is our policy to offer pulmonary retransplantation (re-LTx) to patients with BOS in whom other strategies in the treatment of BOS have failed and in whom no organs other than the lungs are impaired. This strategy has been criticized as a waste of scarce donor organs in the past, since re-LTx was identified as a potential risk factor for survival after LTx. Beside BOS, re-LTx has also been performed for acute graft failure and bronchial healing complications in the early postoperative period after LTx. In outcome analyses, re-LTx was not stratified regarding these three indications. We analyzed the outcome in these three subgroups of re-LTx indications and compared the findings with those of primary LTx candidates at the Hannover Thoracic Transplant Program. In a subanalysis, the outcome after primary

LTx as well as after LTx in patients with pre-LTx mechanical ventilatory support was compared.

Patients and Methods

At our center 614 lungs transplant procedures were performed until January 1, 2004. Of those, 54 (8.5%) were re-LTx procedures. Major indications for primary LTx were pulmonary fibrosis, emphysema, and cystic fibrosis; 45% were female and 55% were male recipients. For acute graft failure after primary LTx, 10 re-LTx procedures were performed, out of which 5 (50%) were initially transplanted for pulmonary fibrosis. Figure 1 depicts the indications for primary LTx compared with those for re-LTx for acute graft failure. In this group only one recipient was female. In 7 patients re-LTx was performed for airway complications, either severe dehiscence of the bronchial anastomosis ($n = 5$) or scarring of the airways with significant obstruction ($n = 2$), when interventional procedures to re-establish the bronchial lumen have failed. In the majority of these patients, the initial reason for transplantation was advanced lung emphysema. In this subgroup, 58% of the recipients were male and 42% were female patients. For chronic graft failure (BOS), 37 re-LTx procedures were performed, as shown in Figure 2. The leading indication in this group was cystic fibrosis (46%) followed by idiopathic pulmonary hypertension (19%). In this group, 65% of patients were female. In the group of primary transplant recipients, mean age was 42 years (16-66 years). For acute graft failure, re-LTx was performed in patients with a mean age of 38 years (range 23-54 years, Figure 3). Recipients in the chronic graft failure group were younger (mean 36 years; range 16-54 years) and patients of the airway complication group were oldest (mean 47 years; range 26-59 years).

Statistical Analysis

Data were prospectively recorded and retrospectively analyzed. All data are expressed as mean $\pm$ SE. Continuous data were analyzed by repeated-measures analysis of variance. For data without repeated measurement, analysis of variance was applied. All data were analyzed with the Statistical Program of Social Sciences (SPSS for MS Windows, version 11.0, SPSS, Inc, Chicago, Ill).

Figure 1. Indications for primary lung transplantation compared with re-LTx for acute graft failure. Tx, Transplantation; gf, graft failure; ppht, primary pulmonary hypertension; pht-sec, secondary pulmonary hypertension.

Figure 2. Indications for re-LTx for airway complications compared with re-LTx for chronic graft failure (BOS). *gf*, Graft failure; *ppht*, primary pulmonary hypertension; *pht-sec*, secondary pulmonary hypertension.

Results

Perioperative survival (1 month) was 91% in the primary transplant cohort. There was no statistical difference when comparing this group with that of re-LTx procedures in patients with airway complications or BOS, which is illustrated in Figure 4. Only in the acute graft failure group was a high early mortality of 20% seen. After 3 months, survival in all groups was similar except for the acute graft failure group, in which the survival was only 71%. In the later follow-up only a 50% 1-year survival was achieved in the acute graft failure group. However, BOS patients and primary LTx patients had comparable 5-year survivals of 62% and 63%, respectively. In the airway complication group, a 2-year survival of only 33% was achieved. For airway complication as well as for acute graft failure, the impairment of long-term survival was of statistical significance compared with BOS and primary LTx patients ($P < .001$).

Table 1 compares the causes of deaths after re-LTx. A similar pattern was found in all groups with the exception of the airway complication group. The leading cause of death was infection, followed by chronic graft failure. In the airway complication group, however, recurrence of dehiscence in 3 recipients was the leading cause of death.

Analyzing a cohort of subsequent primary LTx recipients receiving transplants between January 1998 and 2001 (Figure 5), mechanical ventilation was required before LTx in 39 patients, who were also listed for high-urgency LTx. In the same time period, 112 LTx procedures were performed in 112 elective cases without prior mechanical ventilation. In elective transplants, a perioperative survival of 92% was achieved, leading to a 2-year survival of 78% and a 4-year survival of 64%. However, in the patients with prior mechanical ventilation, reduced survival was found ($P < .01$). In this cohort, perioperative mortality was 21% and 1- and 2-year survival was 50% only.

Figure 3. Age of transplant recipients by indication. *tx*, Transplant; *gf*, graft failure.

Figure 4. Survival of all primary transplant recipients and of re-LTx candidates by indication. *TX*, Transplant; *gf*, graft failure.

TABLE 1. Causes of death after re-LTx

	First LTx (n = 210)	Acute graft failure (n = 6)	Chronic graft failure (n = 16)	Airway complications (n = 6)
Acute rejection	2	0	0	1
Initial graft failure	5	0	1	0
Chronic graft failure	35	1	3	1
Infection	80	4	4	1
Malignancy	8	0	2	0
Other	80	1	6	3

Causes of death of all primary LTx recipients and of re-LTx candidates by indication.

Comparing the incidence of BOS in the group of chronic graft failure patients with primary LTx recipients, similar freedom from BOS was found in a follow-up period of 4 years (Figure 6). Both groups revealed a freedom from BOS of 70% after 2 years and of 50% after 4 years.

Discussion

We have compared the outcome after re-LTx with that after primary LTx at our program and report the data as a single-center experience. All LTx procedures included to this study were performed over a period of more than 15 years. Certainly, early experiences led to different decisions in the later patients. Re-LTx for airway complications were rare in the last 5 years of this study, as were retransplants for acute graft failure. This is in part due to the growing experience from previous patients and due to a “quantum leap” in the quality of lung preservation.⁸ In contrast, re-LTx for chronic graft failure is a current topic, especially with regard to the growing number of recipients in whom severe BOS develops, despite all other efforts at prevention and treatment. However, some trends were noticed in our study: First, airway complications seem to be more common in elderly men with emphysema. Second, re-LTx for acute graft fail-

ure in our cohort was most common in patients with fibrosis and idiopathic pulmonary hypertension, probably indicating a possible role of high pulmonary pressures during the reperfusion period or involvement of immunologic mechanisms on the development of acute lung graft failure. Third, indications for re-LTx in the chronic graft failure cohort were limited to younger patients with an otherwise promising prognosis, such as cystic fibrosis as the indication for primary LTx, with a gender distribution of two-thirds female and one-third males. In this group, long-term survival as well as the incidence of BOS revealed a similar course to that of first-time recipients.

Novick and colleagues⁹ analyzed many aspects of re-LTx a decade ago in a remarkable report on 160 re-LTx procedures performed at 35 centers worldwide. One of the predictors of early survival was the patients’ ambulatory status.⁹ This observation is strongly supported by our data, in that survival was best in chronic graft failure, which represents an elective procedure in ambulatory patients. In contrast, all patients having re-LTx procedures for “airway complications” or “acute graft failure” were on mechanical ventilation at the time of re-LTx and, thus, not ambulatory before the operation. To further support this intriguing finding, we included a previous analysis of first-time transplants stratified by the presence and absence of mechanical ventilatory support before primary LTx. Again, patients on mechanical ventilation showed a 1-year survival of 50% only, which is comparable with the outcome of patients with ventilatory support followed by re-LTx in this study. In the above-mentioned investigation by Novick and associates,⁹ another striking finding was the high incidence of recurrence of BOS in patients having chronic graft failure. A freedom of BOS of only 31% was found after 3 years. This result was clearly improved within the past 10 years to achieve similar outcome to primary transplantation. Another difference is that severe impairment of long-term survival was observed in recipients with BOS stage III. This seems to be attributable to the low number (n = 7), because in our patients the indication for re-LTx was BOS III. In

Figure 5. Cumulative survival of 151 consecutive patients undergoing primary LTx with and without mechanical ventilation before LTx.

Figure 6. Freedom from BOS in long-term survivors after primary LTx and re-LTx for BOS. Differences are not significant (log rank: $P = .09$). TX, Transplant.

another report by the same authors, no difference in survival was observed according to the predominant indication of re-LTx (BOS, airway complication, or acute graft failure).¹⁰ In all groups 1-year survival was below 50%. However, even in these early experiences a significant improvement of survival was found when re-LTx was performed after 1992. Thus, it seems that improvements of re-LTx allow us to distinguish between high- and low-risk indications for re-LTx now. This is leading to two conclusions: First, in registry reports the risk of “retransplantation” should be stratified to “re-LTx for acute graft failure” and “re-LTx for chronic graft failure.” Second, and more provocative, there is no *medical* reason not to do a re-LTx for chronic graft failure, if patients otherwise fulfill the criteria for LTx in general. *Ethical* issues of retransplantation in an era of severe donor organ shortage cannot be answered by medical facts. Furthermore, in a quality of life survey conducted at our program by Künsebeck and coworkers, more than 80% of LTx recipients would decide again for transplantation, regardless the degree of BOS (Figure 7). Only in the BOS III group, 4.7% of patients would not decide for LTx again.

In 1998, an update of the international results on pulmonary retransplantation including 230 patients was published.¹¹ The impairment of ventilatory support to postretransplant outcome was clearly identified. It was also shown that both increasing experience in the field of re-LTx in a single center and re-LTx for BOS performed more than 2 years after primary LTx were associated with reasonable outcome in terms of survival and recurrence of BOS. These findings are now strongly supported by our data. It was concluded by the authors, that high-risk patients, such as those with pre-LTx ventilatory support, “should not be considered for re-LTx with similar priority as other candidates.” This again seems to be a difficult ethical issue, which could be answered in a different way by other than medical professionals, because a survival benefit of 50% for up to 3 years could be demonstrated in these patients. We believe that this problem applies to all patients with ventilatory support before

Figure 7. Surveillance of quality of life (QoL) in lung transplant recipients at the Hannover Thoracic Transplant Program.¹⁵

LTx, not only to retransplant candidates. Another issue in re-LTx is whether it should be offered to children with lung failure after LTx. Clearly, we do not provide evidence regarding re-LTx in children under the age of 16 years. However, in 1998 it was reported that re-LTx should be offered to children with severe graft dysfunction.¹² Although the actuarial survival was shown to be only 58% after 2 years, the option of living donor transplantation was addressed to overcome the problem of availability of suitable grafts. Recently, this opinion was further supported in an updated report,¹³ but we strongly believe that this approach should still be questioned until it has proven its benefit.

In 2003, Brugiere and coworkers¹⁴ reported on their re-LTx experience of 15 patients with BOS in France. In all cases, unilateral LTx was the procedure of choice and a 2-year survival of only 53% was achieved. This raises the question whether long-term outcome was impaired by the technique of single LTx, since most of the recipients in our series received a bilateral re-LTx.

In conclusion, re-LTx represents an effective treatment option for end-stage chronic graft dysfunction. Acceptable long-term results can be achieved when patient selection criteria include “ambulatory patient” and freedom from preoperative mechanical ventilatory support. Re-LTx for acute graft failure and airway complications has become rare because of the very poor outcome. Chance for survival of such re-LTx candidates is comparable with that of recipients who undergo primary LTx with ventilatory support before transplantation. A future debate including ethical aspects seems to be necessary to balance possible individual survival benefits of these high-risk patients and the better long-term outcome of non-ventilator supported transplant candidates.

We thank Ms. Petra Oppelt, who has reviewed statistical analysis in this study as a professional biostatistician.

References

1. Estenne M, Maurer JR, Boehler A, Egan JJ, Frost A, Hertz M, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. *J Heart Lung Transplant*. 2002;21:297-310.
2. Harringer W, Wiebe K, Struber M, Franke U, Niedermeyer J, Fabel H, et al. Lung transplantation: 10-year experience. *Eur J Cardiothorac Surg*. 1999;16:546-54.
3. Jaramillo A, Smith CR, Maruyama T, Zhang L, Patterson GA, Mohanakumar T. Anti-HLA class I antibody binding to airway epithelial cells induces production of fibrogenic growth factors and apoptotic cell death: a possible mechanism for bronchiolitis obliterans syndrome. *Hum Immunol*. 2003;64:521-9.
4. Cairn J, Yek T, Banner NR, Khaghani A, Hodson ME, Yacoub M. Time-related changes in pulmonary function after conversion to tacrolimus in bronchiolitis obliterans syndrome. *J Heart Lung Transplant*. 2003;22:50-7.
5. Hadjiliadis D, Duane-Davis R, Steele MP, Messier RH, Lau CL, Eubanks SS, et al. Gastroesophageal reflux disease in lung transplant recipients. *Clin Transplant*. 2003;17:363-8.
6. Verleden GM, Dupont LJ, Van-Raemdonck D, Vanhaecke J. Effect of switching from cyclosporine to tacrolimus on exhaled nitric oxide and pulmonary function in patients with chronic rejection after lung transplantation. *J Heart Lung Transplant*. 2003;22:908-13.
7. Corris PA. Lung transplantation. Bronchiolitis obliterans syndrome. *Chest Surg Clin N Am*. 2003;13:543-57.
8. Struber M, Wilhelmi M, Harringer W, Niedermeyer J, Anssar M, Kunsebeck A, et al. Flush perfusion with low potassium dextran solution improves early graft function in clinical lung transplantation. *Eur J Cardiothorac Surg*. 2001;19:190-4.
9. Novick RJ, Stitt L, Schäfers HJ, Andréassian B, Duchatelle JP, Klepetko W, et al. Pulmonary retransplantation: Does the indication for operation influence postoperative lung function? *J Thorac Cardiovasc Surg*. 1996;112:1504-14.
10. Novick RJ, Schäfers HJ, Stitt L, Andréassian B, Duchatelle JP, Klepetko W, et al. Recurrence of obliterative bronchiolitis and determinants of outcome in 139 pulmonary retransplant recipients. *J Thorac Cardiovasc Surg*. 1995;110:1402-14.
11. Novick RJ, Stitt LW, Al-Kattan K, Klepetko W, Schäfers HJ, Duchatelle JP, et al. Pulmonary retransplantation: predictors of graft function and survival in 230 patients. Pulmonary Retransplant Registry. *Ann Thorac Surg*. 1998;65:227-34.
12. Huddleston CB, Mendeloff EN, Cohen AH, Sweet SC, Balzer DT, Mallory GB Jr. Lung retransplantation in children. *Ann Thorac Surg*. 1998;66:199-203.
13. Kozower BD, Sweet SC, de la Morena M, Schuler P, Guthrie TJ, Patterson GA, et al. Living donor lung transplantation improves survival following lung retransplantation in children. *J Heart Lung Transplant*. 2005;24:S65.
14. Brugiere O, Thabut G, Castier Y, Mal H, Dauriat G, Marceau A, et al. Lung retransplantation for bronchiolitis obliterans syndrome: long-term follow-up in a series of 15 recipients. *Chest*. 2003;123:1832-7.
15. Kuensebeck HW, Fischer S, Kugler C, Simon A, Gottlieb J, Welte T, et al. Quality of life and bronchiolitis obliterans syndrome in patients after lung transplantation. *Chest*. 2006; submitted.